Ayala Pollack

OphtiMed Rx LTD is an ophthalmic drug development company, led by a team of physicians, scientists, and molecular biology experts. The company is developing a novel molecular therapy for dry Age-related Macular Degeneration (AMD), a common eye disease leading to blindness. This treatment protects retinal cells from senescence (cellular aging) and can halt progression of dry AMD. Our cutting-edge therapy will prevent the loss of vision and independence and bring enormous benefit to patients.